# ImmuPharma PLC Publish Information Note ahead of Euronext listing

- Link: https://www.directorstalkinterviews.com/immupharma-plc-publish-information-note-ahead-of-euronext-listing/412801082
- Published: 2019-12-17T07:22:43+00:00
- Author: Giles Arbor

**ImmuPharma PLC** (LON: IMM), a specialist drug discovery and development company,
has announced that, further to the announcement of 13th December 2019, that its 
shares will be admitted to trading on Euronext Growth Brussels under ticker ‘ALIMM’,
it has today published the Information Note, as required by the Euronext Growth 
Market Rules Book and Belgian financial regulations.

The Information Note is available on ImmuPharma’s website www.immupharma.co.uk. 
Attention is drawn to certain financial information on a period subsequent to that
notified in our Interim Results which is included in Parts II and IV of the Information
Note which is notifiable under AIM Rule 11. This information is set out in the Appendix
below.

Admission to Euronext is expected to take effect from 19 December 2019. This new
listing does not affect the trading of ImmuPharma’s shares on AIM, nor is there 
any intention from the Company to raise additional funds from either AIM or Euronext.

The dual listing on Euronext Growth Brussels aims to further increase the visibility
of ImmuPharma’s shares in continental Europe and with European investors, following
the Company’s recent deal with Avion Pharmaceuticals, who are now funding an international
Phase III trial for the lead programme, Lupuzor™. The investment thesis for ImmuPharma
and specifically Lupuzor™ has been repositioned and the Company looks forward to
providing further progress updates on the Phase III program with Avion, as well 
as entering into additional partnerships outside of the US.

Share on: